Health
NIPRD DG Calls for Local Vaccine Development
By Adedapo Adesanya
The Director-General of the National Institute of Pharmaceutical Research and Development (NIPRD), Dr Obi Adigwe, has called for the inauguration of a National Vaccine Development Technical Working Group with a working secretariat.
This, according to him, will help overcome the challenges hindering vaccine development and production in the country.
He made his position known while making a presentation at a just-concluded National COVID-19 Summit in Abuja.
The summit was put together by the Presidential Steering Committee (PSC) on COVID-19 to fashion out solutions towards ending the pandemic and building back the economy better.
The two-day summit which started with technical sessions was with the theme Pushing through the Last Mile to End the Pandemic and Build Back Better.
The objectives of the event, among others, was to review the country’s COVID-19 response from February 2020 to November 2021- to identify successes, gaps, and lessons learnt; identify resources and develop strategies that will actualize the country’s expressed international commitments towards ending COVID-19 by December 31, 2022; develop an accountability framework for COVID-19 response and health security in Nigeria.
Others included synthesizing the blueprint for Nigeria’s pandemic recovery, reconstruction, health security, and sustainability; and articulating actionable recommendations to President Muhammadu Buhari on the governance structure, resources, and policies needed to end COVID-19 in Nigeria by December 31, 2022, and build back the health system and the economy to better respond to future health-security threats.
The NIPRD DG further called for the establishment of a Vaccine Research and Development Fund with sustainable funding strategy; mapping of human and infrastructural resources and capacities and gaps.
He also put forward that there is a need to set up a 10-year development agenda with key milestones – prioritizing capacity development strategy (human, laboratory and production); identifying and targeting diseases of national priority for vaccine R&D; strengthening linkages among key institutions and the private sector; attracting competent/skilled human resources from the diaspora and strong international cooperation, partnerships and collaboration.
Dr Adigwe, however, identified that political will coupled with the provision of a clear local vaccine development agenda and Research and Development (R&D) prioritization and coordination across efforts are key to achieving local vaccine development and production in Nigeria.
The NIPRD Director-General also revealed that limited access to finance, weak infrastructure (R&D and production), low technological capacity and weak regulatory environments are among the factors frustrating vaccine development and production in Nigeria.
He, therefore, vowed that NIPRD remained committed to continuing its statutory mandate in undertaking R&D activities that will not only improve access to health, but also contribute to the economy, and to national development.
“We have, and will continue to play a lead role in articulating the prioritization of pharmaceutical independence.
“The epidemiological nature of the diseases in Africa, together with the relevant demographic indices, means that a robust engagement with the pharmaceutical sector can provide an innovative model which can uniquely improve healthcare access whilst stimulating socio-economic development.
“Solutions for African healthcare issues must come from Africans who have the willingness and capacity to engage vigorously with relevant issues.
“NIPRD has demonstrated cognate capacity, experience and expertise to lead this intervention and remains partnership-ready to collaborate with other critical stakeholders towards the achievement of health and wealth for all,” he noted.
By Modupe Gbadeyanka
As part of its efforts to safeguard public health in Nigeria, the National Agency for Food and Drug Administration and Control (NAFDAC) has strengthened its regulatory framework for blood and blood products.
A statement signed on Thursday by the Director General of NAFDAC, Prof Mojisola Adeyeye, disclosed that to achieve its goal, the agency will collaborate with relevant authorities and stakeholders to establish a robust regulatory framework that promotes the availability of safe, quality-assured and efficacious blood and blood products, while strengthening public confidence in Nigeria’s healthcare system.
NAFDAC said it intends to partner with government institutions, healthcare providers, blood establishments, development partners and other stakeholders for the robust oversight.
Mrs Adeyeye disclosed that already, her organisation has received the support of the Minister of Health and Social Welfare, Prof Ali Pate.
According to her, NAFDAC has been given the mandate to regulate blood and blood products in line with global best practices and the World Health Organisation (WHO) recommendation that these products be subject to oversight by National Regulatory Authorities (NRAs) for medicines.
She said blood and blood products are classified as essential medicines and must be consistently available with assured quality, safety and affordability, stressing that the aim is to protect patients throughout the blood transfusion chain.
Effective regulatory oversight will support the quality and safety of blood products from donor assessment and collection through testing, processing, storage, transportation and use, the NAFDAC chief noted.
Several African countries, including Egypt, Ghana, South Africa, Tanzania, Zimbabwe, Senegal and Rwanda, have already established regulatory oversight of blood and blood products by their NRAS, she added.
Mrs Adeyeye pointed out that NAFDAC’s renewed regulatory preparedness builds on its broader transformation into a modern, science-based regulatory authority.
Already, it has attained WHO Maturity Level 3, completed WHO Global Benchmarking ML3 re-assessment, obtained WHO prequalification for its drug laboratory, and established internationally accredited laboratory and quality management systems. These capabilities provide a strong foundation for the effective regulation of blood and blood products.
As part of its preparedness, NAFDAC has established a dedicated Vaccines, Biologicals and Medical Devices Registration and Regulation Directorate to oversee the registration and regulation of these products.
The agency established a Vaccines, Biologicals and Medical Devices Laboratory Services many years ago, but became a Directorate in 2024, responsible for quality control, including laboratory testing and lot release, while the Directorate of Evaluation and Research provides oversight of Good Manufacturing Practices. An ultra-modern laboratory facility is also being developed to further strengthen its capacity for the assessment and quality control of vaccines and biologics.
By Modupe Gbadeyanka
An organisation known as GoMed Nigeria is offering free reproductive health services to Nigerian students through a digital self-care platform.
This is being delivered through a partnership with the United Nations Population Fund (UNFPA) and the Lagos State Government.
The pilot scheme will be available to students of the University of Lagos. They will enjoy easier and more private access to essential health products, accurate information, and professional support.
Young Nigerians face some of the highest rates of unintended pregnancy and unmet need for contraception in the world.
Cost, distance, stigma, misinformation, and fears about confidentiality routinely stop students from seeking the products and guidance they need, with consequences that include unintended pregnancy, unsafe abortion, sexually transmitted infections and interrupted education.
The self-care platform is designed to remove each of these barriers. Through the platform, students receive free contraceptives and other sexual and reproductive health commodities provided through the Lagos State Ministry of Health and UNFPA, exclusive discounts on health essentials, and fast, discreet delivery directly to campus and student hostels.
Students can also access trusted sexual and reproductive health information and services through UNFPA’s SoftLife 247 and U-Plan platforms. Through U-PLAN, they can chat directly with qualified Family Planning Service Providers to receive accurate information and address their concerns. They can also confidently engage with GoMed’s registered pharmacists for confidential, judgement-free guidance on medicines and other health products.
“Students should be able to get reliable health information and essential products without cost, distance or fear of judgement becoming barriers.
“This platform brings free sexual and reproductive health commodities, other affordable health products and professional guidance together, with discreet delivery directly to students on campus,” the chief executive of GoMed Nigeria, Mr Anthony Edeki, said.
Also speaking, UNFPA in Nigeria Resident Representative, Muriel Mafico, said, “As the UN agency mandated for “Sexual and Reproductive Health and Rights”, we are committed to reducing preventable maternal deaths and addressing the unmet need for family planning, including by providing and overseeing access to life-saving commodities worldwide.
“Working alongside our partners, we’re helping roll out the digital Self-Care Platform—so that vital, life-changing information can reach more people, more easily. Together, we want to empower Nigeria’s next generation to make informed health choices and achieve stronger health outcomes and a brighter future.”
By Modupe Gbadeyanka
A financing framework to accelerate the electrification of health facilities nationwide has been approved by the federal government.
The approval was announced at the third meeting of the Inter-Ministerial Steering Committee (IMSC) of the Nigeria Power for Health Initiative (NPHI), a presidential programme jointly coordinated by the Federal Ministries of Power and Health and Social Welfare.
The committee was constituted to ensure reliable electricity in at least 30 per cent of Nigeria’s health facilities by the end of 2027.
At the meeting, chaired by the Minister of State for Health and Social Welfare, Mr Isiaq Salako, and co-chaired by the Minister of Power, Mr Joseph Tegbe, members of the Inter-Agency Technical Committee (IATC) presented the recommendations under consideration.
Speaking at the meeting, Mr Salako said the Steering Committee approved a financing framework to mobilise investment for healthcare electrification, alongside a facility energy management framework requiring participating hospitals to build sustainable systems for managing their energy infrastructure.
He said the committee also cleared eight (8) private sector proposals for further engagement, drawn from about 70 submissions received during the National Healthcare Electrification Investor Matchmaking Week in Lagos.
The Health Minister added that Energy Management Teams are already in place at federal tertiary hospitals, with state governments being encouraged to set up similar structures. The initiative will now be institutionalised through dedicated budgetary provisions and a full-time Project Coordination Unit to oversee implementation.
On his part, Mr Tegbe declared that the initiative must now move from announcements to actual project delivery.
Describing the NPHI as one of the President Bola Tinubu administration’s flagship programmes, he said the emphasis should shift towards commissioning completed projects that Nigerians can see for themselves, rather than further groundbreaking ceremonies and public messaging.
He emphasised the need for teaching hospitals, state hospitals, and primary healthcare centres to be fully energised, noting that the Rural Electrification Agency has already energised 5 Federal Teaching Hospitals and several other health facilities nationwide.
He also tied the initiative directly to patient outcomes, arguing that dependable power would end hospitals’ reliance on emergency generators, and pledged that the Ministry would continue to prioritise the initiative’s funding needs while ensuring value for money.
